Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tolerability of a Two Week Treatment With Asasantin Extended Release 200/25 mg Capsules b.i.d., Compared to Reduced Dose During the First Week of Treatment in a Double-blind, Randomised, Placebo Controlled Parallel Group Comparison Trial in Healthy Female and Male Subjects

NCT02269228 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02269228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02269228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tolerability of a Two Week Treatment With Asasantin Extended Release 200/25 mg Capsules b.i.d., Compared to Reduced Dose During the First Week of Treatment in a Double-blind, Randomised, Placebo Controlled Parallel Group Comparison Trial in Healthy Female and Male Subjects
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
February 29, 2000
Completion date
Not reported
Enrollment
100 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy